Smithfield Trust Co Purchases 980 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Smithfield Trust Co raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 55.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,739 shares of the company’s stock after purchasing an additional 980 shares during the quarter. Smithfield Trust Co’s holdings in Teva Pharmaceutical Industries were worth $50,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Renaissance Technologies LLC raised its holdings in Teva Pharmaceutical Industries by 13.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after buying an additional 1,031,400 shares during the last quarter. Maple Rock Capital Partners Inc. increased its position in Teva Pharmaceutical Industries by 68.3% in the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after acquiring an additional 1,770,000 shares during the period. Truist Financial Corp raised its stake in shares of Teva Pharmaceutical Industries by 7.0% during the second quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock valued at $63,135,000 after acquiring an additional 254,483 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Teva Pharmaceutical Industries by 0.5% during the third quarter. Swiss National Bank now owns 3,342,900 shares of the company’s stock worth $60,239,000 after purchasing an additional 15,300 shares during the period. Finally, National Pension Service grew its stake in shares of Teva Pharmaceutical Industries by 107.3% in the third quarter. National Pension Service now owns 3,170,640 shares of the company’s stock worth $57,135,000 after purchasing an additional 1,640,940 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 0.2 %

NYSE:TEVA opened at $17.12 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a twelve month low of $9.35 and a twelve month high of $19.31. The company has a fifty day moving average of $17.70 and a 200-day moving average of $17.30.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. UBS Group upped their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Barclays raised their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.